HC Wainwright

G1 Therapeutics Inc (NASDAQ: GTHX), a clinical-stage biopharmaceutical company that focuses on novel oncology therapeutics, boasts three drug candidates that address "potential blockbuster" markets, according to H.C. Wainwright. The Analyst H.C. Wainwright's Edward White initiated...

Cesca Therapeutics Inc (NASDAQ: KOOL) is poised to make much headway with its automated CAR-T manufacturing platform CAR-TXpress, according to H.C. Wainwright.  CAR-T-cell therapy is a method of treating cancer by using a patient's immune system cells —  T cells —...

Jounce Therapeutics Inc (NASDAQ: JNCE) shares are tumbling Thursday in reaction to the abstract data for JTX-2011 that was made available in advance of an American Society of Clinical Oncology presentation.  JTX-2011, the company's lead product candidate, is a monoclonal antibody that...

Aerpio Pharmaceuticals Inc (OTC: ARPO), an OTC-listed company specializing in drug development for ocular diseases, earned a bullish review Wednesday. The interest in the stock can only go higher, as the company seeks to up-list the shares on the Nasdaq in the coming months, according to H.C....

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) announced Tuesday the approval of its Tavalisse for chronic immune thrombocytopenia — an achievement prompting a 14-percent pop in its stock price. Analysts echoed investor enthusiasm, with H.C. Wainwright increasing its price target from $6.70 to $8...

Palatin Technologies, Inc. (NYSE: PTN), a biopharmaceutical company that focuses on treatments for diseases with significant unmet medical needs, boasts a lead asset, bremelanotide, that has an "arousing number of major boxes checked," according to H.C. Wainwright. The Analyst H.C....

Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a Cambridge, Massachusetts-based developer of targeted protein therapeutics, has been showing promising clinical data for TPT-based cancer treatments. The stock could see significant upside if later-stage bladder cancer trials set for mid-2018 prove to...

The U.S. Food and Drug Administration sent an unfavorable Complete Response Letter last week to Agile Therapeutics Inc (NASDAQ: AGRX) regarding approval for the Twirla contraceptive patch. The letter also included concerns at a third-party manufacturer, Corium International Inc (NASDAQ: CORI...

Checkpoint Therapeutics Inc (NASDAQ: CKPT), a nano-cap therapeutics company that focuses on developing anti-cancer agents, has lost more than half of its value over the past few months but some analysts are bullish on the longer-term picture. The Analyst H.C. Wainwright's Joseph Joseph...

Commercial-stage biopharma company Corium International Inc (NASDAQ: CORI) reported Thursday 19 percent revenue growth for its fiscal year fourth quarter of 2017, while its loss per share narrowed to 36 cents from 42 cents. The company also detailed a slew of upcoming catalysts, including a Dec....

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) on Tuesday reported second-quarter earnings, which consisted of a better than expected loss per share (53 cents versus expectations for 62 cents)and a revenue beat ($35.6 million versus expectations for $32.03 million). Sales of the company's only...

Shares of TESARO Inc (NASDAQ: TSRO) were trading higher by nearly 2 percent early Thursday morning after the U.S. Food and Drug Administration granted approval to the company's intravenous version of its therapy to treat nausea and vomiting in adults undergoing chemotherapy. An oral version of the...

Strata Skin Sciences, Inc. (NASDAQ: SSKN), a nano-cap medical technology company that develops, commercializes and markets innovative products for the treatment of dermatologic conditions, has a more than 400 percent upside, according to HC Wainwright & Co's Joseph Pantginis. Pantginis...

Despite a more than 200-percent gain in MannKind Corporation (NASDAQ: MNKD)'s stock over the past month alone analysts at H.C. Wainwright see even further upside ahead. The firm's Oren Livnat initiates coverage of MannKind's stock with a Buy rating and $7 price target, which represents a gain of...

Following the failure of Axovant Sciences Ltd (NASDAQ: AXON)'s late-stage MINDSET study, which evaluated its Alzheimer's treatment candidate intepirdine, Baird said its bull thesis is blown out. However, HC Wainwright said the setback is not the end of the world for the company. Baird...